Skip to main content
EJNMMI Research
Figure 5 | EJNMMI Research

Figure 5

From: A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

Figure 5

TACs of [ 11 C]erlotinib (top) and [ 18 F]afatinib (bottom) after tariquidar treatment. TACs are averaged over three animals. Mutations: A549 (wild type), H1975 (L858R/T790M), and HCC827 (exon 19 deletion). Tumor and background were manually outlined on the basis of an additional [18F]FDG scan, which was performed directly after the TKI-PET scan was finished.

Back to article page